REG - Abingdon Health PLC - US tax credit agreement

Abingdon HealthAnnouncement

Today 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260527:nRSa7375Fa&default-theme=true

RNS Number : 7375F  Abingdon Health PLC  27 May 2026

 

Abingdon Health plc

("Abingdon Health", the "Group" or the "Company")

 

US tax credit agreement

 

York, UK and Madison, WI, USA, 27 May 2026: Abingdon Health plc (AIM: ABDX)
(OTCQB: ABDXF), a leading international developer, manufacturer and regulatory
services provider for rapid diagnostic tests and med-tech, announces that its
US subsidiary, Abingdon Health USA, Inc., has entered into a Business
Development Tax Credit Agreement with the Wisconsin Economic Development
Corporation ("WEDC"). WEDC serves as the state's agency for economic
development, fostering job growth and business expansion.

 

Under the agreement, Abingdon Health USA, Inc. has been certified as eligible
to earn up to US$370,000 in performance-based Wisconsin tax credits over a
three-year period commencing 1 January 2026. The credits comprise up to
US$320,000 linked to the creation of new full-time roles and up to US$50,000
linked to qualifying capital investment at the Group's facilities in Wisconsin
over this period.  The amount of credits the Company will receive is
contingent on the number of jobs created and amount of capital invested.

 

This award reflects the continued growth of the Group's US operations and
supports the ongoing expansion of its facilities in Madison, Wisconsin, which
serve as Abingdon Health's North American base for development, manufacturing
and commercial activities.

 

John W. Miller, Secretary and CEO of WEDC, said "Abingdon's decision to locate
in Wisconsin and continue to grow here reflects the strength of our state's
leadership in the field of biohealth and biotechnology, our outstanding
research institutions, and our highly trained workforce.  WEDC is proud to
partner with Abingdon as they open this next chapter."

 

Chris Yates, President of Abingdon Health USA Inc, said: "We are grateful for
this award from the Wisconsin Economic Development Corporation, which serves
as a welcome endorsement of our commitment and investment in Wisconsin and our
positioning in the US market. These tax credits will support our expansion at
University Research Park in Madison, including the creation of additional
skilled roles as Abingdon Health USA continues to grow to meet customer demand
across the United States."

 

Any shareholders wishing to keep up to date with Abingdon Health news, please
email abingdon@walbrookpr.com

 

Enquiries:

 

 Abingdon Health plc                           www.abingdonhealth.com/investors/ (http://www.abingdonhealth.com/investors/)
 Chris Hand, Executive Chairman                                                         Via Walbrook PR
 Tom Hayes, CFO

 Cavendish Capital Markets Limited (Sole Broker and Nominated Adviser)                    Tel: +44 (0)20 7220 0500
 Geoff Nash / Isaac Hooper / Joe Smith (Corporate Finance)

 Nigel Birks (Life Science Specialist Sales)

 Walbrook PR (Media & Investor Relations)      Tel: +44 (0)20 7933 8780 or abingdon@walbrookpr.com
                                               (mailto:abingdon@walbrookpr.com)
 Paul McManus / Alice Woodings                 Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654

 

 

About Abingdon Health

 

Abingdon Health Group is a leading med-tech contract service provider
offering its services to an international customer base.

 

The Group's CDMO
(https://www.abingdonhealth.com/services/lateral-flow-cdmo-development)
(Contract Development and Manufacturing Organisation) expertise offers lateral
flow product development
(https://www.abingdonhealth.com/services/your-complete-lateral-flow-partner/)
, regulatory strategy support, technology transfer and manufacturing services
(https://www.abingdonhealth.com/services/lateral-flow-scale-up-technical-transfer)
for customers looking to develop new assays or transfer existing
laboratory-based assays to a lateral flow format.  Abingdon Health has the
internal capabilities to take lateral flow projects, in areas such as
infectious disease and clinical testing
(https://www.abingdonhealth.com/services/your-complete-lateral-flow-partner/)
, including companion diagnostics
(https://www.abingdonhealth.com/services/companion-diagnostics-ivd-cdmo) ,
animal health and environmental testing, from initial concept through to
routine manufacturing; from idea to commercial success.

 

Abingdon's regulatory services
(https://www.abingdonhealth.com/services/regulatory-services/) companies,
Compliance Solutions (Life Sciences) and IVDeology, provide a broad range of
regulatory services to the in vitro diagnostic and wider medical device
industry, to support customers in bringing products to market across a range
of territories including the USA, EU and the UK. Its consultancy services
range from design, implementation and maintenance of quality management
systems, preparation of technical files for regulatory approvals, part-time
and interim management support, auditing both internal and external,
management reviews and presentations, training and mentoring.  The Company's
subsidiary, Abingdon Analytical Ltd, offers analytical testing and performance
evaluation
(https://www.abingdonhealth.com/services/performance-evaluation-services/) to
generate the required technical and data for regulatory approval for lateral
flow and other in vitro diagnostic assays from its Doncaster, England
facilities.

 

Founded in 2008, Abingdon Health is headquartered in York, England with
laboratories in Doncaster, England and laboratories and commercial offices in
Madison, Wisconsin, USA.

 

Abingdon Health's brochures
(https://www.abingdonhealth.com/knowledge-centre/brochures-guides)  outlines
the comprehensive support the Group can now provide to its international
customers.  For more information visit: www.abingdonhealth.com
(https://urldefense.proofpoint.com/v2/url?u=http-3A__www.abingdonhealth.com_&d=DwMFAg&c=euGZstcaTDllvimEN8b7jXrwqOf-v5A_CdpgnVfiiMM&r=b40MoFA_Q_fdsT77LXB5t3JFUZjlmpd2MVbmgvoBIOo&m=5rmPWmSeAYNtvo-wVGL_4V7p0wZ2qRPhbqDj6E6FHnhVakMVyzvk7wZG1jS6vI4P&s=Cd1Yy0EoU5vx33xedoTE3bCKbljgDOIRD8ol-bb59BM&e=)
.

 

LEI - 213800XFI4WV3FBILO20

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  AGRSEIFFMEMSEFI



            Copyright 2019 Regulatory News Service, all rights reserved